

To the Press:

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

21 January 2014

Exiqon launches Next Generation Sequencing services

Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced the launch of its new Next Generation Sequencing services for microRNAs and other RNAs.

Exiqon's Next Generation Sequencing services provide a complete sample-to-answer solution including biological interpretation of customer's results. Results are delivered within 4-6 weeks of sample submission. All customers receive results and data analyses in the form of a highly advanced interactive report. The interactive report summarizes results in simple tables and diagrams and provides easy access to identify interesting microRNAs and genes through use of Exiqon's proprietary miRSearch bioinformatics search tool which saves time and effort compared to traditional literature and database searches by rapidly presenting relevant information.

"This product offering is based on years of collaboration with our customers and numerous man-years of product development. Valuable customer input has defined the importance of combining high quality, fast turnaround time and thorough in depth reporting that can be readily understood by customers without prior training in Next Generation Sequencing" said Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller

The new offer for Next Generation Sequencing services complements Exiqon's existing portfolio of services for qPCR and microarray profiling and allows Exiqon to leverage 9 years of experience in servicing customers with high quality data through modern service laboratories.

Exiqon's Next Generation Sequencing services integrate technical support in the planning phase with advanced sample preparation, library preparation, sequence generation based on state-of-the-art equipment and proprietary data analysis. These services address the need in basic research to reveal known as well as unknown microRNAs and other RNAs. Exiqon also offers a full range of LNA™-enhanced qPCR products for validation of targets identified by Next Generation Sequencing and LNA™ products for any down-stream functional analysis.

Additional information is available at www.exiqon.com/NGS-services

A sample of the data report can be downloaded at www.exiqon.com/Is/Documents/Scientific/NGS-Service-Flyer.pdf

Additional information

Lars Kongsbak, Presidents and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

Henrik M. Pfundheller, SVP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)

1/2



About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells and body fluids. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to target new medicines based on miRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.

